After 14 to 25 weekly administrations of GcMAF all patients had very low serum Nagalase levels equivalent to those of healthy control, indicating that these patients are tumor-free

Ориентировочное время чтения: 2 мин.
 
Ссылка на статью будет выслана вам на E-mail:
Введите ваш E-mail:

Abstract Title:

Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.

Abstract Source:

Transl Oncol. 2008 Jul ;1(2):65-72. PMID: 18633461

Abstract Author(s):

Nobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto

Article Affiliation:

Nobuto Yamamoto

Abstract:

Serum Gc protein (known as vitamin D(3)-binding protein) is the precursor for the principal macrophage-activating factor (MAF). The MAF precursor activity of serum Gc protein of prostate cancer patients was lost or reduced because Gc protein was deglycosylated by serum alpha-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells. Therefore, macrophages of prostate cancer patients having deglycosylated Gc protein cannot be activated, leading to immunosuppression. Stepwise treatment of purified Gc protein with immobilized beta-galactosidase and sialidase generated the most potent MAF (termed GcMAF) ever discovered, which produces no adverse effect in humans. Macrophages activated by GcMAF develop a considerable variation of receptors that recognize the abnormality in malignant cell surface and are highly tumoricidal. Sixteen nonanemic prostate cancer patients received weekly administration of 100 ng of GcMAF. As the MAF precursor activity increased, their serum Nagalase activity decreased. Because serum Nagalase activity is proportional to tumor burden, the entire time course analysis for GcMAF therapy was monitored by measuring the serum Nagalase activity. After 14 to 25 weekly administrations of GcMAF (100 ng/week), all 16 patients had very low serum Nagalase levels equivalent to those of healthy control values, indicating that these patients are tumor-free. No recurrence occurred for 7 years.

Article Published Date : Jun 30, 2008
Study Type : Human Study
Additional Links
SubstancesGc protein-derived macrophage activating factor (GcMAF) : CK(42) : AC(7)
DiseasesProstate Cancer : CK(1586) : AC(463)
Pharmacological ActionsImmunomodulatory: CK(1287): AC(358)
Additional KeywordsSignificant Treatment Outcome : CK(3038) : AC(366)

Список научных работ и исследований по GcMaf

Внимание! Предоставленная информация не является официально признанным методом лечения и несёт общеобразовательный и ознакомительный характер. Мнения, выраженные здесь, могут не совпадать с точкой зрения авторов или сотрудников МедАльтернатива.инфо. Данная информация не может подменить собой советы и назначение врачей. Авторы МедАльтернатива.инфо не отвечают за возможные негативные последствия употребления каких-либо препаратов или применения процедур, описанных в статье/видео. Вопрос о возможности применения описанных средств или методов к своим индивидуальным проблемам читатели/зрители должны решить сами после консультации с лечащим врачом.

Оставьте комментарий

Войти с помощью: